1887

Chapter 45 : The Current State of the U.S. Food and Drug Administration Process and Regulations for Diagnostic Laboratory Assays

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

The Current State of the U.S. Food and Drug Administration Process and Regulations for Diagnostic Laboratory Assays, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817282/9781555817275_Chap45-1.gif /docserver/preview/fulltext/10.1128/9781555817282/9781555817275_Chap45-2.gif

Abstract:

The United States (US) Food and Drug Administration (FDA) regulates the sale and distribution of in vitro diagnostic devices (IVDs), commonly referred to as laboratory assays or laboratory tests. This chapter provides an overview of (i) the FDA process for risk-based classification and regulation of IVDs, (ii) the FDA methods used to assess performance of IVDs prior to their clearance or approval for release in marketing and distribution to diagnostic laboratories, (iii) the laws that impact clinical laboratories that are participating in FDA clinical trials, and (iv) the process by which the FDA conducts postmarket regulation of IVDs and associated postmarket performance. The chapter helps the reader to understand the process by which the FDA approves a laboratory assay, and describes the different processes used during FDA review. It also describes the risk categories the FDA uses to determine the type of process for review. The chapter also helps the reader to understand the premarket approval (PMA) forms, requirements, and process, and the need to recognize the importance of good clinical practices (GCPs), good manufacturing practices (GMPs), and quality systems regulations (QSR) in the FDA approval process. It talks about the requirements related to 510(k) notification to the FDA, the pre-investigational device exemption process, and the part that the Office of In Vitro and Radiological Health plays during the approval process. Finally, the chapter reviews the limitations inherent to current FDA processes.

Citation: Wolk D, Whitfield N, Marlowe E, Marshall M. 2014. The Current State of the U.S. Food and Drug Administration Process and Regulations for Diagnostic Laboratory Assays, p 809-817. In Garcia L (ed), Clinical Laboratory Management, Second Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817282.ch45

Key Concept Ranking

Randomized Controlled Trial
0.62163746
Clinical Trials
0.4880723
0.62163746
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 45.1
Figure 45.1

PMA review milestones in total FDA calendar days—domestic inspections. From http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm077795.pdf (accessed March 18, 2013). doi:10.1128/9781555817282.ch45.f1

Citation: Wolk D, Whitfield N, Marlowe E, Marshall M. 2014. The Current State of the U.S. Food and Drug Administration Process and Regulations for Diagnostic Laboratory Assays, p 809-817. In Garcia L (ed), Clinical Laboratory Management, Second Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817282.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817282.chap45
1. Bastian, H.,, P. Glasziou,, and I. Chalmers. 2010. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 7(9):e1000326. [PubMed][CrossRef]
2. Campbell, G. 2008. Statistics in the world of medical devices: the contrast with pharmaceuticals. J. Biopharm. Stat. 18(1):419. [PubMed][CrossRef]
3.Centers for Disease Control and Prevention. 2004. Current CLIA regulations. http://wwwn.cdc.gov/clia/regs/toc.aspx (accessed December 25, 2012).
4. Emmadi, R.,, J. B. Boonyaratanakornkit,, R. Selvarangan, et al. 2011. Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. J. Mol. Diagn. 13(6):583604. [PubMed][CrossRef]
5.Food and Drug Administration. 1998. FDA Modernization Act of 1997: guidance for the device industry on implementation of highest priority provisions. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094527.htm, updated May 1, 2009.
6.Food and Drug Administration. 1998. New Section 513(f)(2): evaluation of automatic class III designation, guidance for industry and CDRH staff. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080195.htm, updated August 17, 2012.
7.Food and Drug Administration. 2009. General controls for medical devices. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ucm055910.htm (accessed December 25, 2012).
8.Food and Drug Administration. 2009. Goals and initiatives for the IDE program #D95-1 (blue book memo). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080583.htm (accessed April 27, 2013).
9.Food and Drug Administration. 2009. In vitro diagnostic devices: guidance for the preparation of 510(k) submissions. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094533.htm (accessed April 27, 2013).
10.Food and Drug Administration. 2009. Regulatory information: Public Health Service Act. http://www.fda.gov/RegulatoryInformation/Legislation/ucm148717.htm (accessed April 27, 2013).
11.Food and Drug Administration. 2010. Guidance for industry and FDA staff. In vitro diagnostic (IVD) device studies: frequently asked questions. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM071230.pdf (accessed April 27, 2013).
12.Food and Drug Administration. 2010. Medical devices: pre-market notification (510k). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/default.htm (accessed April 27, 2013).
13.Food and Drug Administration. 2011. Combination product definition. http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm118332.htm (accessed April 27, 2013).
14.Food and Drug Administration. 2011. Federal Food, Drug, and Cosmetic Act (FD&C Act). http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm (accessed April 27, 2013).
15.Food and Drug Administration. 2011. Medical devices: presentation: quality system regulation 21 CFR 820. http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm126252.htm (accessed April 27, 2013).
16.Food and Drug Administration. 2011. Medical devices: quality system (QS) regulation/medical device good manufacturing practices. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/QualitySystemsRegulations/default.htm (accessed April 27, 2013).
17.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Part 807: establishment registration and device listing for manufacturers and initial importers of devices. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=807 (accessed April 27, 2013).
18.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Part 814: premarket approval of medical devices. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=814 (accessed April 27, 2013).
19.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Part 862: Clinical Chemistry And Clinical Toxicology Devices http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=862 (accessed December 25, 2012).
20.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Part 864: hematology and pathology devices http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=864 (accessed April 27, 2013).
21.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Sec. 864.4010: general purpose reagent. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=864.4010 (accessed December 25, 2012).
22.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Sec. 864.4020: analyte specific reagents. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=864.4020 (accessed December 25, 2012).
23.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Part 866: immunology and microbiology devices. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=866 (accessed December 25, 2012).
24.Food and Drug Administration. 2012. CFR - Code of Federal Regulations Title 21. Subchapter h—medical devices. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=809.3 (accessed December 25, 2012).
25.Food and Drug Administration. 2012. Device advice: investigational device exemption (IDE). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/default.htm (accessed April 27, 2013).
26.Food and Drug Administration. 2012. Medical devices – IDE approval process. Part 812: investigational device exemptions. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm046164.htm#pre_ide (accessed April 27, 2013).
27.Food and Drug Administration. 2013. Device registration and listing. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/default.htm (accessed April 27, 2013).
28.Food and Drug Administration. 2013. How to prepare an abbreviated 510(k). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm134574.htm (accessed April 27, 2013).
29.Food and Drug Administration. 2013. How to prepare a special 510(k). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm134573.htm (accessed April 27, 2013).
30.Food and Drug Administration. 2013. Medical devices: regulatory controls. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ucm2005378.htm#class_1 (accessed April 27, 2013).
31. Gammie, A. J. 2008. For the proposition: for the diagnosis of viral infections, commercial assays provide more reliable results than do in-house assays. Rev. Med. Virol. 18(2):7376. [PubMed][CrossRef]
32. Hayden, R. T.,, X. Yan,, M. T. Wick, et al. 2012. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J. Clin. Microbiol. 50(2):337345. [PubMed][CrossRef]
33. Mansfield, E.,, T. J. O'Leary,, and S. I. Gutman. 2005. Food and Drug Administration regulation of in vitro diagnostic devices. J. Mol. Diagn. 7(1):27. [PubMed][CrossRef]
34. Meier, K. L.,, and S. Gitterman. 2011. Drug-device trials for infectious diseases: CDRH perspective. Clin. Infect. Dis. 52(Suppl 4): S367S372. [PubMed][CrossRef]
35. O'Kane, D. 2010. An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but. . . . Clin. Pharmacol. Ther. 88(6):746748. [PubMed][CrossRef]
36. Theodorsson, E. 2012. Validation and verification of measurement methods in clinical chemistry. Bioanalysis 4(3):305320. [PubMed][CrossRef]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error